Sana Clinics Dusseldorf GmbH

Düsseldorf, Germany

Sana Clinics Dusseldorf GmbH

Düsseldorf, Germany
Time filter
Source Type

Kempf K.,Sana Clinics Dusseldorf GmbH | Kruse J.,Justus Liebig University | Martin S.,Sana Clinics Dusseldorf GmbH
Diabetes Technology and Therapeutics | Year: 2010

Background: As healthy diet and physical activity can improve glucometabolic control in patients with type 2 diabetes, lifestyle changes should be the basis for each therapy. The only tool to visualize immediate effects of food pattern and exercise on blood glucose levels is self-monitoring of blood glucose (SMBG). Therefore, the aim of the 12-week lifestyle intervention ROSSO-in-praxi was to evaluate the impact of an SMBG-structured motivation and education program on glucometabolic and health parameters in diabetes patients not treated with insulin. Methods: Participants (n=405) generated a seven-point blood glucose diurnal profile every 4 weeks, including actual weight, waist circumference, and steps/day. At baseline and the end of the study, glycated hemoglobin A1c (HbA1c), blood pressure, and cholesterol levels, lifestyle changes, and well-being (SF36 and Center for Epidemiologic Studies Depression Scale questionnaires) were assessed. Results: Three hundred twenty-seven participants (81%) completed the program and significantly improved quality of diet and physical activity, accompanied by an increase of >2,300 steps/day. Participants significantly reduced weight, body mass index, waist circumference, blood glucose, blood pressure, low-density lipoprotein cholesterol, and HbA1c by 0.3% (all P<0.001), accompanied by increased physical and mental health and reduced depression measurements. Weight loss was significantly associated with overall improvements of glucometabolic and health parameters and mean reduction of 0.05% HbA1c/kg. Conclusions: The evaluated SMBG-structured lifestyle intervention is applicable to motivate individuals with type 2 diabetes for lifestyle changes. Integration of this short-term, highly motivational, and low-cost intervention into basic therapy for patients without insulin therapy could strengthen patient empowerment in order to change lifestyle and to improve glucometabolic and general health. © 2010, Mary Ann Liebert, Inc.

Kempf K.,Dusseldorf Catholic Hospital Group | Kempf K.,Sana Clinics Dusseldorf GmbH | Kruse J.,Justus Liebig University | Martin S.,Dusseldorf Catholic Hospital Group
Diabetes Technology and Therapeutics | Year: 2012

Background: Self-monitoring of blood glucose (SMBG) is a simple tool to monitor the effects of lifestyle change on blood glucose. Recently, the ROSSO-in-praxi Study demonstrated that addition of SMBG to a 12-week lifestyle intervention was associated with significant improvements in glucometabolic control and quality of life in insulin-naive patients with type 2 diabetes mellitus (T2DM). So far it is unknown if this short-term intervention also has long-term effects. Therefore, participants were followed up for a mean period of 2 years. Methods: Participants (n=327) were asked by mail for current weight, hemoglobin A1c (HbA1c), performance of SMBG, and quality of life (SF36 and CES-D questionnaires). Participants who did not reply were contacted by phone. Results: Two hundred twenty-eight participants (70%) completed the follow-up. During the 12-week lifestyle intervention they had significantly reduced weight (2.2kg) and HbA1c (0.3%; P<0.001 each). After 2 years they achieved a further reduction of weight (0.2kg; P<0.001), whereas HbA1c increased again, remaining 0.1% lower than baseline. The numbers of depressed participants remained stable during follow-up, whereas physical and mental health-related quality of life remained better compared with baseline. During follow-up 20% of participants continued SMBG daily, 35% several times a week, and 33% irregularly. It is interesting that participants with daily SMBG demonstrated an HbA1c decrease of 0.3% at time of follow-up, whereas in those who stopped SMBG HbA1c increased by 0.1% (P=0.05). Conclusions: Integration of a short-term, motivational, and low-cost intervention into basic therapy of T2DM has had beneficial long-term effects on weight and quality of life and, if SMBG was continued daily, also on HbA1c. © Copyright 2012, Mary Ann Liebert, Inc. 2012.

Kempf K.,Heinrich Heine University Düsseldorf | Kempf K.,Sana Clinics Dusseldorf GmbH | Herder C.,Heinrich Heine University Düsseldorf | Erlund I.,Finnish National Institute for Health and Welfare | And 13 more authors.
American Journal of Clinical Nutrition | Year: 2010

Background: Coffee consumption is associated with a decreased risk of type 2 diabetes. Suggested mechanisms underlying the association have included attenuation of subclinical inflammation and a reduction in oxidative stress. Objective: The aim was to investigate the effects of daily coffee consumption on biomarkers of coffee intake, subclinical inflammation, oxidative stress, glucose, and lipid metabolism. Design: Habitual coffee drinkers (n = 47) refrained for 1 mo from coffee drinking; in the second month they consumed 4 cups of filtered coffee/d and in the third month 8 cups of filtered coffee/d (150 mL/cup). Blood samples were analyzed by gas chromatography-mass spectrometry, bead-based multiplex technology, enzyme-linked immunosorbent assay, or immunonephelometry. Results: Coffee consumption led to an increase in coffee-derived compounds, mainly serum caffeine, chlorogenic acid, and caffeic acid metabolites. Significant changes were also observed for serum concentrations of interleukin-18, 8-isoprostane, and adiponectin (medians: -8%, -16%, and 6%, respectively; consumption of 8 compared with 0 cups coffee/d). Serum concentrations of total cholesterol, HDL cholesterol, and apolipoprotein A-I increased significantly by 12%, 7%, and 4%, respectively, whereas the ratios of LDL to HDL cholesterol and of apolipoprotein B to apolipoprotein A-I decreased significantly by 8% and 9%, respectively (8 compared with 0 cups coffee/d). No changes were seen for markers of glucose metabolism in an oral-glucose-tolerance test. Conclusions: Coffee consumption appears to have beneficial effects on subclinical inflammation and HDL cholesterol, whereas no changes in glucose metabolism were found in our study. Furthermore, many coffee-derived methylxanthines and caffeic acid metabolites appear to be useful as biomarkers of coffee intake. © 2010 American Society for Nutrition.

Schinner S.,Heinrich Heine University Düsseldorf | Futh R.,Heart Center | Kempf K.,Dusseldorf Catholic Hospital Group | Kempf K.,Sana Clinics Dusseldorf GmbH | And 6 more authors.
Cardiovascular Diabetology | Year: 2011

Objective: Diabetes mellitus type 2 (DM2) is a risk factor for coronary heart disease (CHD). While there is a clear correlation of fasting blood glucose (FBG) and 2 h post-challenge blood glucose values (2h-BG) with microvascular complications, the risk for CHD conferred by glucose dysregulation antecedent to DM2 is less clear. Therefore, we investigated associations of FBG and 2h-BG values with the prevalence of CHD assessed by coronary angiography as the most sensitive diagnostic tool.Research Design and Methods: Coronary angiography was performed in 1394 patients without known DM. Capillary blood glucose was analyzed before and 2 h after an oral glucose tolerance test. Associations between FBG as well as 2h-BG levels and the risk for CHD were assessed by logistic regression analysis.Results: 1064 (75%) of patients were diagnosed with CHD. 204 (15%) were diagnosed with so far unknown DM2, 274 (20%) with isolated impaired fasting glucose (IFG), 188 (13%) with isolated impaired glucose tolerance (IGT) and 282 (20%) with both, IGT and IFG. We found a continuous increase in the risk for CHD with fasting and post-challenge blood glucose values even in the subdiabetic range. This correlation did however not suggest clear cut-off values. The increase in risk for CHD reached statistical significance at FBG levels of > 120 mg/dl (Odds Ratio of 2.7 [1.3-5.6] and 2h-BG levels > 140 mg/dl (141-160 mg/dl OR 1.8 [1.1-2.9], which was however lost after adjusting for age, sex and BMI.Conclusions: In our study population we found a continuous increased risk for CHD at fasting and 2h-BG levels in the sub-diabetic glucose range, but no clear cut-off values for cardiovascular risk. © 2011 Schinner et al; licensee BioMed Central Ltd.

Kolb H.,Hagedorn Research Institute | Kempf K.,Sana Clinics Dusseldorf GmbH | Martin S.,Sana Clinics Dusseldorf GmbH | Stumvoll M.,University of Leipzig | Landgraf R.,German Diabetes Foundation
Diabetes Research and Clinical Practice | Year: 2010

Self-monitoring of blood glucose (SMBG) has been considered one major breakthrough in diabetes therapy because, for the first time, patients were able to determine their blood glucose levels during daily life. It seems obvious that this must be of advantage to disease management and clinical outcome, but it has become a nightmare for those trying to provide evidence. Randomised controlled trials have yielded inconsistent results on a benefit of SMBG-based treatment strategies not only in type 2 but - surprisingly - also in type 1 and gestational diabetes. Despite this, SMBG is being considered indispensible in intensive insulin treatment, but is being debated for other clinical settings. When considering the non-RCT based reasons for recommending SMBG in type 1 and gestational diabetes it becomes apparent that the same reasons also apply to type 2 diabetes. © 2009 Elsevier Ireland Ltd. All rights reserved.

Kempf K.,Sana Clinics Dusseldorf GmbH | Martin S.,Sana Clinics Dusseldorf GmbH
Diabetes, Stoffwechsel und Herz | Year: 2010

Introduction: Neuropathy is a common chronic complication of diabetes mellitus, associated with discomfort and pain, substantially compromising the everyday life of sufferers. In a previous pilot trial we were able to demonstrate that high-frequency external muscle stimulation (HFEMS) effectively reduces neuropathic symptoms. More recently, we assessed the impact of HFEMS on neuropathic symptoms in a larger cohort in a 'real life' study design. Methods: In this study, 414 patients with symptomatic diabetic neuropathy used the HFEMS device HiToP®191 (gbo Medizintechnik AG). Symptom intensity and frequency were assessed in standardized telephone interviews before and at the end of the first week, at the end of the fourth week, and three weeks after finishing therapy. Results: HFEMS significantly reduced the intensity and frequency of all neuropathic symptoms in feet and lower legs, as well as disruptions during sleep (p< 0.0001 for all symptoms). Post-therapy symptoms recurred, but remained less intense and less frequent compared to baseline. In total, 88.4% of patients were responders and reported a reduction of symptoms with greater improvements seen in the female participants (p = 0.036), as well as in those with higher HbA1c (p = 0.027) and neuropathy symptom scores (NSS) at baseline (p = 0.0002). Conclusion: HFEMS improves symptoms of diabetic neuropathy. Free of side effects and effective in the majority of patients, it represents a valuable non-pharmacological therapy option for patients with diabetic neuropathy.

Kempf K.,Sana Clinics Dusseldorf GmbH | Futh R.,Heart Center | Futh R.,University of Witten | Dinh W.,Heart Center | And 12 more authors.
International Journal of Cardiology | Year: 2011

Background/objectives: Guidelines recommend screening all patients with cardiovascular disease by oral glucose tolerance test (OGTT). Due to its time-consuming protocol, costs and overall inconvenience performance of OGTT is limited in cardiological routine. Thus, we aimed to identify easily available parameters that could help to reduce the numbers of OGTT needed. Methods: OGTTs (n = 1215) were performed in all patients without known type 2 diabetes mellitus (T2DM) that were submitted to the heart center Wuppertal with known or suspected coronary artery disease for an elective coronary angiography from January to October 2007. Results: 31.4% had normal glucose tolerance; prediabetes was present in 50.7%, whereas 17.9% were newly diagnosed with T2DM. Thus, 998 OGTTs did not result in the new diagnosis of so far undiagnosed T2DM. Multiple logistic regression and receiver operated characteristic analyses demonstrated that fasting blood glucose (FBG) ≥ 90 mg/dl and age ≥ 55 years were predictive for so far undiagnosed T2DM. Considering these two parameters 81.1% (= sensitivity) of so far undiagnosed T2DM patients would have been identified (specificity = 63.4%) and the number of OGTTs could have been reduced from 1215 to 541. Conclusions: About 70% of patients were newly diagnosed with impaired glucose metabolism. FBG ≥ 90 mg/dl and age ≥ 55 years were predictive for so far undiagnosed T2DM and OGTTs could be reduced by 55.5%. This should alleviate the implementation of the current guidelines in daily cardiological practice. © 2010 Elsevier Ireland Ltd. All rights reserved.

Loading Sana Clinics Dusseldorf GmbH collaborators
Loading Sana Clinics Dusseldorf GmbH collaborators